The impact of vehicle on the relative potency of skin-sensitizing chemicals in the local lymph node assay.
The identification and characterization of chemicals that possess skin-sensitizing potential are typically performed using predictive tests. However, human exposure to skin-sensitizing chemicals often occurs via a matrix (vehicle) that differs from that used in these tests. It is thus important to account for the potential impact of vehicle differences when undertaking quantitative risk assessment for skin sensitization. This is achieved through the application of a specific sensitization assessment factor (SAF), scaled between 1 and 10, when identifying an acceptable exposure level. The objective of the analysis described herein is to determine the impact of vehicle differences on local lymph node assay (LLNA) EC3 values (concentrations of test chemical required to provoke a 3-fold increase in lymph node cell proliferation). Initially, the inherent variability of the LLNA was investigated by examining the reproducibility of EC3 values for 14 chemicals that have been tested more than once in the same vehicle (4:1 acetone:olive oil, AOO). This analysis reveals that the variability in EC3 value for these chemicals following multiple assessments is <5-fold. Next, data from the literature and previously unpublished studies were compiled for 18 chemicals that had been assessed in the LLNA using at least 2 of 15 different vehicles. These data demonstrate that often the variability in EC3 values observed for a given chemical in different vehicles is no greater than the 5-fold inherent variability observed when assessing a chemical in the same vehicle on multiple occasions. However, there are examples where EC3 values for a chemical differ by a factor of more than 10 between different vehicles. These observations were often associated with an apparent underestimation of potency (higher EC3 values) with predominantly aqueous vehicles or propylene glycol. These data underscore the need to consider vehicle effects in the context of skin-sensitization risk assessments.
Jowsey
Ian R
IR
Unilever Safety and Environmental Assurance Centre, Colworth Park, Sharnbrook, Bedfordshire, UK. ian.jowsey@smith-nephew.com
Clapp
Catherine J
CJ
Safford
Bob
B
Gibbons
Ben T
BT
Basketter
David A
DA
D000485:Allergens / Q000494:pharmacology*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007114:Immunization / Q000379:methods*; D023441:Local Lymph Node Assay; D008198:Lymph Nodes / Q000187:drug effects*; D051379:Mice; D008808:Mice, Inbred CBA; D009930:Organic Chemicals / Q000494:pharmacology; D014677:Pharmaceutical Vehicles / Q000494:pharmacology*; D015203:Reproducibility of Results; D018570:Risk Assessment; D012997:Solvents / Q000494:pharmacology
D000485:Allergens; D009930:Organic Chemicals; D014677:Pharmaceutical Vehicles; D012997:Solvents